{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The primary endpoint is the overall response rate (ORR) based on the IWG-2006 criteria, which includes complete remission (CR), partial remission (PR), and hematologic improvement (HI).","groups":[{"description":"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.\n\nStarting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.\n\nEltrombopag: Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.\n\nDecitabine: Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.","id":"OG000","title":"Eltrombopag + Decitabine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One participant was not evaluable for response.","reportingStatus":"POSTED","timeFrame":"28 days","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}